General
Preferred name
CLOPERASTINE
Synonyms
CLOPERASTINE HYDROCHLORIDE ()
Cloperastine (HCl) ()
HT-11 hydrochloride ()
Cloperastine (hydrochloride) ()
CLOPERASTINE HYDROCLORIDE ()
Cloperastina ()
NSC-758635 ()
HT-11 ()
P&D ID
PD009413
CAS
3703-76-2
132301-89-4
14984-68-0
Tags
available
drug
nuisance
Drug Status
approved
experimental
investigational
Max Phase
2.0
Drug indication
Cough
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Cloperastine hydrochloride inhibits the hERG K+ currents in a concentration-dependent manner with an IC50 value of 27 nM[1].
DESCRIPTION
Cloperastine hydrochloride is a blocker of sodium channel protein type 8.
(Enamine Bioactive Compounds)
DESCRIPTION
Cloperastine hydrochloride (HT-11 hydrochloride) is a type of flavonoid.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
4
Compound Sets
15
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
MedChem Express Bioactive Compound Library
NPC Screening Collection
Nuisance compounds in cellular assays
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
44
Molecular Weight
329.15
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
2
cLogP
4.93
TPSA
12.47
Fraction CSP3
0.4
Chiral centers
1.0
Largest ring
6.0
QED
0.74
Structural alerts
1
CAD
Nuisance compounds
Custom attributes
(extracted from source data)
Target
HT
Potassium Channel
Histamine Receptor
MOA
Potassium Channel antagonist
Pathway
Membrane Transporter/Ion Channel
GPCR/G protein
Neuroscience
Source data

